cardiovascular

MindHYVE’s ChironAI Showcased at Peshawar Institute of Cardiology’s CME on Cardiovascular Imaging Innovation”

PESHAWAR, Pakistan, Nov. 18, 2025 /PRNewswire/ -- The Peshawar Institute of Cardiology – Medical Teaching Institute (PIC-MTI) hosted a high-profile Radiology…

2 weeks ago

The Hidden Genetic Threat Putting 1 in 5 at Cardiovascular Disease Risk: Global Experts Call for Action on Elevated Lipoprotein(a)

Cardiovascular disease (CVD) kills nearly 18 million people each year, more than all cancers combined1,2Elevated lipoprotein(a) or Lp(a), an inherited condition…

2 months ago

Novo Nordisks Wegovy cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease

Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart attack, stroke…

3 months ago

Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension

Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3In the…

3 months ago

New REDUCE-IT Analyses Presented at ESC 2025 Include Data Showing VASCEPA/VAZKEPA (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

-- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High-Risk or…

3 months ago